 NORCROSS, Ga., Dec. 11, 2020 GLOBE NEWSWIRE -- Galectin Therapeutics Inc. NASDAQ:GALT, the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer, has been invited to make a presentation, entitled Belapectin, a Galectin-3 Inhibitor in Phase 2b3 for the Treatment of NASH Cirrhosis, at the 4th Annual Digital NASH Summit . Dr. Boudes will be speaking at 09:00 AM EST on December 17, 2020. 